MP060DETERMINING TREATMENT PREFERENCE FOR TOLVAPTAN IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): DEVELOPMENT OF A DISCRETE CHOICE EXPERIMENT (DCE) FOR USE AS A CLINICAL STUDY ENDPOINT | Zendy

AI Assistant Blog Pricing

MP060DETERMINING TREATMENT PREFERENCE FOR TOLVAPTAN IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): DEVELOPMENT OF A DISCRETE CHOICE EXPERIMENT (DCE) FOR USE AS A CLINICAL STUDY ENDPOINT

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.